Is Aprea Therapeutics, Inc. (APRE) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.0% / 30% | 221.7% / 30% | 0.0% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 0.0% / 33% | 221.7% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 0.0% / 33% | 95.3% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 0.0% / 33% | 221.7% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 0.0% / 33% | 95.3% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | -79205.7% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -74.6% | |
| Return on Assets (ROA) | -41.4% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$13M |
| Free Cash Flow | -$13M |
| Current Ratio | 5.6 |
| Total Assets | $16M |
Price & Trading
| Last Close | $0.70 |
| 50-Day MA | $0.77 |
| 200-Day MA | $1.26 |
| Avg Volume | 2.2M |
| Beta | 1.6 |
|
52-Week Range
$0.55
| |
About Aprea Therapeutics, Inc. (APRE)
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Aprea Therapeutics, Inc. (APRE) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Aprea Therapeutics, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Aprea Therapeutics, Inc.'s debt ratio?
Aprea Therapeutics, Inc.'s debt ratio is 0.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.0%.
What are Aprea Therapeutics, Inc.'s key financial metrics?
Aprea Therapeutics, Inc. has a market capitalization of $8M. Return on equity stands at -74.6%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.